CD274 and lung adenocarcinoma: The study showed that 62.0% (160/258) of the lung adenocarcinoma group had PD-L1 <1%, and only 38.0% (98/258) had PD-L1 ≥1%, suggesting that the expression of immune checkpoints is low in lung adenocarcinoma patients [15].